E
Opus Genetics, Inc. IRD
$0.865 $0.00430.50% NASDAQ
Recommendation
Prev Close
$0.8607
Volume
230,666
Avg Vol (90D)
226,569
Market Cap
$39.15M
Dividend & Yield
--
52-Week Range
$0.65 - $2.18
P/E (TTM)
--
EPS (TTM)
-$2.04
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath
4/15/2025 - GuruFocus
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath
4/15/2025 - Globe Newswire
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns
4/11/2025 - Globe Newswire
Opus Genetics (IRD) Receives Buy Rating with Promising Gene Therapy Pipeline IRD Stock News
4/11/2025 - GuruFocus
Craig-Hallum bullish on Opus Genetics, initiates with a Buy
4/11/2025 - The Fly
Opus Genetics initiated with bullish view at Craig-Hallum
4/11/2025 - The Fly
Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch
4/9/2025 - Simply Wall St
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of ...
4/8/2025 - GuruFocus
Opus Genetics announces data from patient in Phase 1/2 trial of OPGx-LCA5
4/8/2025 - The Fly
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
4/8/2025 - Globe Newswire
Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting ...
4/7/2025 - GuruFocus
Opus Genetics urges stockholders to vote for company's nine board nominees
4/7/2025 - The Fly
Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress
4/7/2025 - Globe Newswire
Opus Genetics Terminates Purchase Agreement with Lincoln Park
4/4/2025 - TipRanks Financial Blog
Opus Genetics to Participate in Upcoming Investor Conference in April
4/2/2025 - GuruFocus
Opus Genetics to Participate in Upcoming Investor Conference in April
4/2/2025 - Globe Newswire
Opus Genetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
4/2/2025 - Simply Wall St
Opus Genetics (NASDAQ:IRD) Issues Earnings Results, Misses Estimates By $0.93 EPS
4/1/2025 - Ticker Report
Opus Genetics price target lowered by $1 at JonesResearch, here's why
4/1/2025 - The Fly
Opus Genetics Announces Financial Results for Full Year 2024
3/31/2025 - GuruFocus
Opus Genetics reports FY24 EPS ($2.15) vs. (46c) last year
3/31/2025 - TipRanks Financial Blog
Opus Genetics sees cash runway into 2H26
3/31/2025 - TipRanks Financial Blog
Opus Genetics announces expected 2025 growth drivers
3/31/2025 - TipRanks Financial Blog
Opus Genetics announces expected 2025 growth drivers
3/31/2025 - The Fly
Opus Genetics sees cash runway into 2H26
3/31/2025 - The Fly
Income Statement
Total Revenue (TTM)
$10.99M
EBITDA (TTM)
-$34.07M
EBIT (TTM)
-$34.07M
Net Income (TTM)
-$57.53M
Balance Sheet
Total Assets (Q)
$36.86M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$11.30M
Book Value Per Share (Q)
$0.213
Cash Flow
Cash from Operations (TTM)
-$25.58M
Cash from Investing (TTM)
$1.21M
Cash from Financing (TTM)
$4.19M
Net Change in Cash (TTM)
-$20.18M
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.88
7-Day Total Return
13.83%
30-Day Total Return
-8.14%
60-Day Total Return
-22.07%
90-Day Total Return
-13.50%
Year to Date Total Return
-31.35%
1-Year Total Return
-47.58%
2-Year Total Return
-85.63%
3-Year Total Return
-63.03%
5-Year Total Return
--
52-week Low
Apr 10, 2025 - $0.65
52-week High
Jul 18, 2024 - $2.18
Valuation
Market Cap
$39.15M - Nano Cap
Enterprise Value
$27.67M
Price/Sales (TTM)
2.38
Price/Book (Q)
4.04
Dividends and Shares
Shares Outstanding
30.36M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
ir.opusgtx.com
Phone Number
984 884 6030
Address
8 Davis Drive
Durham, NC 27709
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases. The company offers... more
NASDAQ 04/29/2025 4:00PM Eastern Quotes delayed